Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, October 28 at 2:00 PM ET

Register Free →
CLEATUS
Get CLEATUS

BARDA DRIVe EZ-BAA (EZBAA - 22-100-SOL-00003)

Active
DRIVeEZBAA22100SOL00003Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

The BARDA DRIVe Easy Broad Agency Announcement (EZ-BAA-22-100-SOL-00003) is a solicitation by the Department of Health and Human Services to advance transformative tools, products, and technologies for health security threats. Effective from October 18, 2022, through October 18, 2027, this initiative supports research and development across various stages of technological readiness, including early R&D, clinical validation, and manufacturing. The program utilizes a two-phase submission process where businesses, academia, and nonprofits first submit an abstract for market research, followed by an invitation to provide a full proposal. The solicitation is organized around multiple Areas of Interest (AOIs) that are frequently updated, paused, or revised through amendments to align with public health priorities. Key research areas have included vaccine innovation, diagnostic platforms for remote settings, medical countermeasures for radiation syndrome, and technologies for acute respiratory distress syndrome. While the overall announcement remains open until 2027, individual AOIs have specific deadlines and statuses; for example, Amendment 037 closed initial submission acceptance for Healing Lungs, ReBooT, and Type to Treat effective April 22, 2025. Eligible applicants must maintain active registration in SAM.gov, and awardees are required to share de-identified data with BARDA to support government research objectives.

General Info

BARDA solicitation for health security R&D tools and technologies through October 18, 2027.

Agency

Department Of Health And Human Services → Barda - Aspr / Daappo / Barda Dcma

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)

Place of Performance

DC

Set-Aside

NONE

Documents

38

Amendment 003 for EZ-BAA on Healing Lungs

PDF, High priority: read this first5 pages · amendment
High

Amendment 004 for EZ-BAA Vaccines on Demand

PDF, High priority: read this first3 pages · amendment
High

Amendment 006 for EZ-BAA on Lab at Home AOI

PDF, High priority: read this first5 pages · amendment
High

Amendment 007 for EZ-BAA AOI #24: REPAIR

PDF, High priority: read this first3 pages · amendment
High

Amendment 010 for EZ-BAA AOI #24: REPAIR

PDF, High priority: read this first4 pages · amendment
High

Amendment 016 to EZ-BAA BAA22 100 SOL00003 Pausing AOI #24 REPAIR

PDF, High priority: read this first3 pages · amendment
High

Amendment 017 to EZ-BAA BAA22 100 SOL00003 Reopening and Revising AOI #20 DRIVe Forward

PDF, High priority: read this first4 pages · amendment
High

Amendment #022 to EZBAA-22-100-SOL-00003

PDF, High priority: read this first5 pages · amendment
High

Amendment #022 to EZBAA-22-100-SOL-00003 Pausing AOI #27 and Updating AOI #20 Topics and Deadline

PDF, High priority: read this first24 pages · amendment
High

Amendment #022 to EZBAA-22-100-SOL-00003 Pausing AOI #27 and Updating AOI #20 Topics and Deadline

PDF, High priority: read this first5 pages · amendment
High

Amendment #022 to EZBAA-22-100-SOL-00003: Pausing AOI #27 and Updating AOI #20 Topics and Deadline

PDF, High priority: read this first6 pages · amendment
High

Amendment #022 to EZBAA-22-100-SOL-00003 Pausing AOI #27 and Updating AOI #20 Topics and Submission Details

PDF, High priority: read this first4 pages · amendment
High

Amendment #0 25 to EZBAA22 100 SOL00003 Reopens and Revises AOI #24 RePAIR for Radiation MCMs

PDF, High priority: read this first4 pages · amendment
High

Amendment #030: Influenza Vaccine Innovation

PDF, High priority: read this first6 pages · amendment
High

Amendment #031: Reopening AOI #24 RePAIR

PDF, High priority: read this first3 pages · amendment
High

Amendment #033 to EZBAA-22-100-SOL-00003 Reopening AOI #15 ReDIRECT and Removing ROM Requirement

PDF, High priority: read this first3 pages · amendment
High

Amendment #033 to EZBAA-22-100-SOL-00003 Reopening AOI #15 ReDIRECT and Removing ROM Requirement

PDF, High priority: read this first4 pages · amendment
High

Amendment #033 to EZBAA-22-100-SOL-00003 Reopening AOI #15 ReDIRECT and Removing ROM Requirement

PDF, High priority: read this first4 pages · amendment
High

Amendment #033 to EZBAA-22-100-SOL-00003 Reopens AOI #15 ReDIRECT and Removes ROM Requirement

PDF, High priority: read this first5 pages · amendment
High

Amendment #033 to EZBAA-22-100-SOL-00003 Reopens AOI #15 ReDIRECT and Removes ROM Requirement

PDF, High priority: read this first3 pages · amendment
High

Amendment 036 to EZBAA-22-100-SOL-00003 Healing Lungs Closing Date Update

PDF, High priority: read this firstamendment
High

Amendment 037 to DRIVe EZ Broad Agency Announcement EZBAA-22-100-SOL-00003

PDF, High priority: read this firstamendment
High

Amendment #0 to EZBAA22 100 SOL00003: Updates to DRIVe Forward AOI and Pausing AOI 26

PDF, High priority: read this first3 pages · amendment
High

Amendment #0 to EZBAA22 100 SOL00003: Updates to DRIVe Forward AOI and Pausing AOI 26

PDF, High priority: read this first5 pages · amendment
High

Amendment to EZBAA22 100 SOL00003: DRIVe Forward AOI Reopened

PDF, High priority: read this first5 pages · amendment
High

Amendment to EZBAA22 for Agnostic Diagnostic AOI

PDF, High priority: read this first3 pages · amendment
High

Amendment to EZBAA22 for Digital MCMs and Other AOIs

PDF, High priority: read this first4 pages · amendment
High

Amendment to EZBAA22 for Lab at Home and Healing Lungs

PDF, High priority: read this first3 pages · amendment
High

Amendment to EZBAA22: Stopping Secondary Spread

PDF, High priority: read this first5 pages · amendment
High

Amendment to EZBAA22: Updates on ARDS Research Areas

PDF, High priority: read this first6 pages · amendment
High

BARDA DRIVe Easy Broad Agency Announcement (EZ-BAA) for Innovative Health Security R&D

PDF, High priority: read this first5 pages · baa
High

BARDA DRIVe Easy Broad Agency Announcement (EZ-BAA) for Innovative Health Security R&D

PDF, High priority: read this first4 pages · baa
High

BARDA DRIVe Easy Broad Agency Announcement (EZ-BAA) for Innovative Health Security R&D

PDF, High priority: read this first7 pages · baa
High

BARDA DRIVe Easy Broad Agency Announcement (EZ-BAA) for Innovative Health Security R&D

PDF, High priority: read this first20 pages · baa
High

BARDA DRIVe Easy Broad Agency Announcement (EZ-BAA) for Innovative Health Security R&D

PDF, High priority: read this first3 pages · baa
High

Amendment 005 for EZ-BAA BAA22 100 SOL00003

PDF, Medium priority3 pages · amendment
Medium

Amendment 011 for EZ-BAA: Closing and Updating AOIs

PDF, Medium priority3 pages · amendment
Medium

Amendment to EZBAA22 100 SOL00003 for AOIs ReBooT and FASTx

PDF, Medium priority3 pages · amendment
Medium

AI Contract Breakdown

Uniform Contract Format

Contract not broken down yet

CLEATUS splits the solicitation into Uniform Contract Format (UCF) sections: scope, pricing, deliverables, and evaluation criteria.

Timeline

PhaseSolicitation
Posted

Solicitation

Response Deadline

Submission deadline

Response Deadline

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyDepartment Of Health And Human Services → Barda - Aspr / Daappo / Barda Dcma
Contacts1 person available
OfficeWASHINGTON, DC, 20515, USA
Organization / AgencyDepartment Of Health And Human Services → Barda - Aspr / Daappo / Barda Dcma
Office AddressWASHINGTON, DC, 20515, USA
Contacts
BARDA DCMA DRIVe Team
contact@example.gov

Full Description

Show more

This announcement serves as a reissuance of the BARDA DRIVe EZ-BAA, now known as EZ-BAA-22-100-SOL-00003. This announcement hereby supersedes and replaces prior iterations of the BARDA DRIVe EZ-BAA (e.g. BAA-20-100-SOL-0002). Please reference the attached announcement and applicable amendments for specifics. Additionally, please visit https://drive.hhs.gov/. 


_______


Amendment 001:  This amendment to the EZBAA hereby opens the following research areas of interest ("AOI"). Please review the amendment for details of each AOI, including closing dates: 


AOI #15: ReDIRECT
AOI #16: Lab at Home
AOI #17: Digital MCMs
AOI #18: Host-Directed Therapeutics
AOI #19: Healing Lungs
AOI #20: DRIVe Forward
AOI #21: Vaccines on Demand
AOI #22: ReBooT
AOI #23: Host-Based Diagnostics


_____


11/8/22 - Please see Amendment 002 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003.  Under this Amendment, BARDA is:


1. Adding the the following Area of Interest (AOI):


    AOI #24:  REPAIR


2. Clarifying an adminstrative error. 


_____


11/14/22 - Please see Amendment 003 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003.  Under this Amendment, BARDA is:


1. Revising the following Area of Interest (AOI): 


    AOI #19: Healing Lungs


_____


12/15/22 - Please see Amendment 004 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003.  Under this Amendment, BARDA is:


1. Updating the closing date for the following Area of Interest (AOI): 


    AOI #21: Vaccines on Demand


______


1/11/23 - Please see Amendment 005 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is:


1. Pausing the following Area of Interest (AOI) by establishing a new closing date of February 15, 2023 at 12:00PM ET:


    AOI #15: ReDIRECT


______


2/1/23 - Please see Amendment 006 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 


1. Updating the closing date for the following Area of Interest (AOI): 


AOI #19: Healing Lungs 


2. Updating the closing date for the following Area of Interest (AOI): 


AOI #17: Digital MCMs  


3. Updating the closing date for the following Area of Interest (AOI): 


AOI #16: Lab at Home 


4. Revising the following Area of Interest (AOI): 


AOI #16: Lab at Home


______


2/3/23 - Please see Amendment 007 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 


1. Updating the closing date for the following Area of Interest (AOI): 


AOI #24: REPAIR


______


5/1/23 - Please see Amendment 008 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 


1. Adding the following Area of Interest (AOI): 


AOI #25: FASTx


2. Updating the language in Section III (F) of the Easy Broad Agency Announcement titled “Plus (+) Phase”.


______


5/18/23 - Please see Amendment 009 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 


1. Reopening the following Area of Interest (AOI), which is reopened to support project Next Gen: 


AOI #21: Vaccines on Demand


______


5/25/23 - Please see Amendment 010 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 


1. Revising the following Area of Interest (AOI): 


AOI #24: REPAIR


2. Updating the closing date for the following Area of Interest (AOI): 


AOI #24: REPAIR


______


6/27/23 - Please see Amendment 011 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 


1. Closing the following Area of Interest (AOI): 


AOI #18: Host-Directed Therapeutics 


2. Closing the following Area of Interest (AOI): 


AOI #23: Host-Based Diagnostics


3. Updating the closing date for the following Area of Interest (AOI): 


AOI #19: Healing Lungs


______


9/13/23 - Please see Amendment 012 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 


1. Updating the closing date for the following Area of Interest (AOI): 


AOI #16: Lab at Home


2. Updating the closing date for the following Area of Interest (AOI): 


AOI #17: Digital MCMs


3. Updating the closing date for the following Area of Interest (AOI): 


AOI #19: Healing Lungs


4. Revising the following Area of Interest (AOI): 


AOI #16 Lab at Home


5. Adding the following Area of Interest (AOI): 


AOI #26: Agnostic Diagnostic 


_______


9/14/23 - Please see Amendment 013 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 


1. Pausing the following Area of Interest (AOI): 


AOI #20: DRIVe Forward


________


9/26/23 - Please see Amendment 014 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 


1. Pausing the following Area of Interest (AOI): 


AOI #21: Vaccines on Demand


_________


10/26/23 - Please see Amendment 015 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 


1. Updating the closing date for the following Area of Interest (AOI): 


AOI #22: ReBoot


2. Updating the closing date for the following Area of Interest (AOI): 


AOI #25: FASTx


3. Revising the following Area of Interest (AOI): 


AOI #22: ReBoot


4. Revising the following Area of Interest (AOI): 


AOI #25: FASTx


___________


10/30/23 - Please see Amendment 016 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 


1. Pausing the following Area of Interest (AOI): 


AOI #24: REPAIR


__________


11/15/23 - Please see Amendment 017 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 


1. Reopening the following Area of Interest (AOI): 


AOI #20: DRIVe Forward 


2. Revising the following Area of Interest (AOI): 


AOI #20: DRIVe Forward 


__________


12/13/23 - Please see Amendment 018 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 


1. Updating the closing date for the following Area of Interest (AOI): 


AOI #16: Lab at Home


2. Revising the following Area of Interest (AOI): 


AOI #16: Lab at Home


3. Pausing the following Area of Interest (AOI): 


AOI #17: Digital MCMs


4. Updating the closing date for the following Area of Interest (AOI): 


AOI #19: Healing Lungs


__________


01/03/24 - Please see Amendment 019 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 


1. Reopening the following Area of Interest (AOI): 


AOI #15: ReDIRECT


2. Revising the following Area of Interest (AOI): 


AOI #15: ReDIRECT


__________


01/10/24 - Please see Amendment 020 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 


1. Pausing the following Area of Interest (AOI): 


AOI #26: Agnostic Diagnostic


2. Adding a topic to the following Area of Interest (AOI): 


AOI #20: DRIVe Forward


3. Updating the closing date for the following Area of Interest (AOI):


AOI #20: DRIVe Forward


_________


01/18/24 - Please see Amendment 021 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 


1. Adding the following Area of Interest (AOI): 


AOI #27: Stopping Secondary Spread


__________


2/5/24 - Please see Amendment 022 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003.  Under this Amendment, BARDA is:


1. Pausing the following research Area of Interest (AOI):


AOI #27: Stopping Secondary Spread


2. Revise topics for the following research Area of Interest (AOI):


AOI #20: DRIVe Forward


__________


02/12/24 - Please see Amendment 023 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 


1. Reopening the following Area of Interest (AOI): 


AOI #26: Agnostic Diagnostic


__________


02/21/24 - Please see Amendment 024 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 


1. Updating the closing date for the following Area of Interest (AOI): 


AOI #22: ReBooT



2. Updating the closing date for the following Area of Interest (AOI): 


AOI #25: FASTx


__________


03/04/24 - Please see Amendment 025 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 


1. Reopening the following Area of Interest (AOI): 


AOI #24: RePAIR


2. Revising the following Area of Interest (AOI): 


AOI #24: RePAIR


__________


03/12/24 - Please see Amendment 026 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 


1. Updating the closing date for the following Area of Interest (AOI): 


AOI #16: Lab at Home


2. Updating the closing date for the following Area of Interest (AOI): 


AOI #19: Healing Lungs


_________


04/22/24 - Please see Amendment 027 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 


1. Reopening the following Area of Interest (AOI): 


AOI #20: DRIVe Forward


2. Removing two topic areas and adding one topic area to the following Area of Interest (AOI): 


AOI #20: DRIVe Forward


_________


05/01/24 - Please see Amendment 028 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 


1. Updating the closing date for the following Area of Interest (AOI): 


AOI #15: ReDIRECT


2. Updating the closing date for the following Area of Interest (AOI): 


AOI #26: Agnostic Diagnostic


3. Reopening the following Area of Interest (AOI): 


AOI #17: Digital MCMs


4. Revising the following Area of Interest (AOI):


AOI #17: Digital MCMs


__________


05/09/24 - Please see Amendment 029 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 


1. Pausing the following Area of Interest (AOI):


AOI #16: Lab at Home


2. Updating the closing date for the following Area of Interest (AOI):


AOI #19: Healing Lungs


3. Revising the following Area of Interest (AOI):


AOI #19: Healing Lungs


4. Updating the closing date for the following Area of Interest (AOI): 


AOI #24: RePAIR


_________


09/24/24 - Please see Amendment 030 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 


1. Adding the following Area of Interest (AOI):


AOI #28: Influenza Vaccine Innovation


2. Pausing the following Area of Interest (AOI):


AOI #26: Agnostic Diagnostic 


___________


09/30/24 - Please see Amendment 031 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 


1. Reopening the following Area of Interest (AOI):


AOI #24: RePAIR


___________


10/10/24 - Please see Amendment 032 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 


  1. Update the closing date for the following Area of Interest (AOI): AOI #19: Healing Lungs
     
  2. Pause the following Area of Interest (AOI) on 10/31/24: AOI #17: Digital MCMs

___________


10/31/24 - Please see Amendment 033 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is:


  1. Reopen the following Area of Interest (AOI) on 11/1/24:

       AOI #15: ReDIRECT


       2. Remove language requiring a Rough Order of Magnitude (ROM) from the record


11/26/2024 - Please see Amendment 034 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is:


1) Reopen the following Area of Interest (AOI):
AOI #22: ReBooT



2) Revise the following Area of Interest (AOI):
AOI #22: ReBooT



3) Pause the following Area of Interest (AOI):
AOI#24: RePAIR


___________



1/13/2025 - Please see Amendment 035 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is:


1) Reopen the following Area of Interest (AOI) on 1/15/2025:
AOI #16: Lab at Home


2) Open the following Area of Interest (AOI):
AOI #29: Type to Treat



___________


2/14/2025 - Please see Amendment 036 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 


  1. Updating the closing date for the following Area of Interest (AOI): AOI #19: Healing Lung



__________


4/22/2025 - Please see Amendment 037 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this amendment, BARDA is revising the following Areas of Interest (AOI) to close effective immediately:


AOI #19: Healing Lungs


AOI #22: ReBooT 


AOI #29: Type to Treat 


Additional details can be found in the corresponding Amendment 037. 

Similar Contracts

Same NAICS industry code

NAICS: 541714
New
Federal
In Vivo Biodistribution Studies and Bioluminescence ImagingThis subcontract, titled In Vivo Biodistribution Studies and Bioluminescence Imaging, supports biotechnology projects for the Department of Veterans Affairs at the Harry S Truman Memorial Veterans Hospital. The selected provider will conduct animal studies to evaluate AAV vector specificity and off-target transduction. Key technical responsibilities include administering vectors to animal models, utilizing bioluminescence imaging via IVIS to track localization, and performing tissue harvesting for qPCR analysis to generate comprehensive biodistribution data reports. The work will be performed in Columbia, Missouri, and requires strict adherence to AAALAC and FELASA health standards. This opportunity is categorized under NAICS code 541714 and is managed by Rpo East. Interested parties should note the response deadline of November 4, 2026.
Rpo East (36C24E)

POSTED

about 7 hours ago

DEADLINE

in 14 days
View Details
NAICS: 541714
New
Federal
AAV Vector Binding and Internalization Testing (Kidney Tissue)This subcontract, issued by the Department of Veterans Affairs Rpo East for biotechnology projects at the Harry S Truman Memorial Veterans Hospital, involves specialized laboratory testing to verify the binding and internalization of AAV vectors. The selected provider will be responsible for preparing kidney tissue slices, incubating them with modified AAV vectors, and utilizing qPCR platforms, Agilent Fragment Analyzers, and fluorescence microscopy to analyze efficiency. All work must be performed in BSL-2 facilities, and the contractor is required to hold BSL-2 certification. The primary deliverable for this engagement is the provision of detailed validation reports focusing on internalization rates and binding affinity. The project is categorized under NAICS code 541714 and is based in Columbia, Missouri. Interested parties must respond by November 4, 2026.
Rpo East (36C24E)

POSTED

about 7 hours ago

DEADLINE

in 14 days
View Details
NAICS: 541714
New
Federal
AJ12--Development/Production - Kidney GEC-Specific AAV Vector
Solicitation # 36C24E27Q0009
The Department of Veterans Affairs is issuing a Sources Sought notice to identify capable vendors for the development and production of a kidney glomerular endothelial cell specific adeno-associated virus AAV vector. This project, funded by a VA ORD Merit award, aims to create a homing peptide enabled vector platform to target the glomerular endothelium to treat kidney injury and disease while reducing off target transduction. The scope of work is divided into three primary tasks: the engineering and incorporation of targeting peptides into the AAV capsid, testing vector binding and internalization in kidney tissue slices, and evaluating the specificity and efficiency of the modified vector through bioluminescence imaging and in vivo biodistribution studies. Qualified contractors must possess extensive onsite resources, including BSL 2 laboratories, specialized DNA and RNA facilities, and advanced instrumentation such as the Agilent Fragment Analyzer and various qPCR platforms. Vendors must demonstrate proven success in animal and human cell vector delivery and maintain full compliance with AAALAC and FELASA health standards. The government requires quarterly reporting, weekly videoconferences, and biannual face to face meetings. All generated data will be subject to Government Purpose Rights, and contractors must adhere to strict federal records management and information security protocols. Interested parties must submit a capability statement, relevant literature, and socio economic status details under NAICS 541714 by November 4, 2026.
Rpo East (36C24E)

POSTED

about 7 hours ago

DEADLINE

in 14 days
View Details
NAICS: 541714
New
Grant
MPS Platform Development & EngineeringThis subcontract focuses on the development and engineering of Microphysiological Systems and Organ-on-a-Chip platforms to support prime contractors on NIH/NIAID infectious disease projects. The scope of work involves engineering microfluidic devices, optimizing tissue-chip interfaces, and utilizing biocompatible polymers and precision pumps to integrate human variability into hardware and biological interfaces. The ultimate goal is to deliver a validated and reproducible platform that aligns with NIH and FDA guidance regarding New Approach Methodologies. Managed under the National Institutes of Health within the Department of Health and Human Services, the project falls under NAICS code 541714. The solicitation was posted on October 20, 2026, with a response deadline set for January 29, 2027.
National Institutes Of Health

POSTED

1 day ago

DEADLINE

in 3 months
View Details
NAICS: 541714
New
Grant
Translational Centers Using Microphysiological Systems for Infectious Diseases (U54 Clinical Trial Not Allowed)
Solicitation # RFA-AI-28-012
The National Institute of Allergy and Infectious Diseases (NIAID) has issued solicitation RFA-AI-28-012 to establish a consortium of Translational Centers Using Microphysiological Systems for Infectious Diseases (TCMID). The primary objective is to refine and validate human tissue models using Microphysiological Systems (MPS) to a level consistent with regulatory qualifications, thereby promoting their adoption by product developers and reducing reliance on laboratory animals. This initiative aligns with NIH and FDA guidance on New Approach Methodologies (NAMs) to accelerate the development of safer medical interventions by capturing human variability and patient-specific characteristics. The program is structured around an Administrative Core, a Qualification Core, and Scientific Cores, with a heavy emphasis on technical readiness, reproducibility, and regulatory acceptance. Key deliverables include the validation of assays for specific endpoints and the submission of regulatory packages. Applicants must be domestic entities, as foreign organizations and foreign subawards are strictly prohibited. Required personnel must possess deep expertise in infectious diseases, MPS platforms, bioinformatics, and FDA submission processes. Applications are due by January 29, 2027, and must be submitted via the NIH ASSIST system or approved institutional system-to-system solutions. Evaluation is based on an overall impact score considering the project's significance, the suitability of the investigators, and the quality of the institutional environment. Mandatory application components include a Data Management and Sharing Plan and a Benchmarks and Timeline PDF not exceeding six pages. Awardees must also adhere to strict cybersecurity incident reporting guidelines, notifying HHS within 48 hours of any discovery.
National Institutes Of Health

POSTED

1 day ago

DEADLINE

in 3 months
View Details
NAICS: 541714
New
Grant
Immune Tolerance Network (UM1 Clinical Trial Required)
Solicitation # RFA-AI-28-005
The National Institutes of Health, under the Department of Health and Human Services, is seeking applications through solicitation RFA-AI-28-005 to continue the Immune Tolerance Network (ITN). This cooperative agreement aims to develop tolerogenic therapies for immune-mediated disorders, specifically focusing on autoimmune diseases, allergic diseases and asthma, and the immune-mediated consequences of transplantation. The network operates through four integrated functional areas: Leadership, Clinical Operations, Core Laboratory, and Bioinformatics. Its primary objectives include designing and conducting clinical trials, performing integrated mechanistic studies, and sharing research results. Eligible applicants include small businesses and other for-profit organizations, though non-domestic entities are ineligible. Applications are evaluated based on scientific and technical merit, with a primary focus on significance and the likelihood of exerting a sustained influence on the research field. Key requirements include maintaining active registrations in SAM.gov, eRA Commons, and Grants.gov, as well as adhering to strict cybersecurity incident reporting and human subject protection protocols. The project requires a minimum effort of 3.6 person months per year for the PD/PI and mandates participation in a kick-off meeting in Bethesda, Maryland, and bi-annual steering meetings. Applications must follow specific page limits for the research strategy subsections and include detailed plans for clinical trial implementation, data management, and biorepository services.
National Institutes Of Health

POSTED

1 day ago

DEADLINE

in 3 months
View Details
NAICS: 541714
New
Federal
Pre-Clinical Models of Infectious Diseases
Solicitation # 75N93027R00003
The National Institute of Allergy and Infectious Diseases (NIAID) is issuing a ramp-on solicitation to award multiple IDIQ base contracts for the Preclinical Models of Infectious Diseases program. This initiative aims to expand the existing pool of contractors capable of developing and refining animal and animal replacement models to evaluate medical countermeasures, such as vaccines, therapeutics, and diagnostics. The program bridges the gap between in vitro testing and clinical evaluation, supporting regulatory submissions and the advancement of countermeasures against priority biodefense and emerging infectious agents. Successful offerors will be eligible to compete for task orders across four specific areas: Small Animal Models, Non-Human Primate Models, Animal Replacement and Non-traditional Animal Models, and the Generation and Distribution of Specialized Reagents. The scope of work emphasizes a wide array of pathogens, including pandemic-potential RNA viruses, antimicrobial-resistant infections, fungal diseases, and neglected tropical diseases. Proposals must be submitted electronically via the NIAID eCPS website, and applicants are required to have a valid NIH eRA Commons account for authentication and secure transmission.
National Institutes Of Health Niaid

POSTED

2 days ago

DEADLINE

in about 2 months
View Details
NAICS: 541714
New
Federal
Alternative Protein Technologies for Military Field Feeding
Solicitation # W911QY27ALTPROTEINS
The US Army Combat Capabilities Development Command Soldier Center is seeking information from Massachusetts-based offerors to identify innovative alternative protein technologies for integration into military rations. The objective is to enhance food supply chain resilience and provide nutrient-dense, lightweight food options for warfighters. Areas of interest include fermentation and biomanufacturing processes, innovative product development for shelf-stable rations, consumer research for military acceptability, and the optional provision of GRAS-certified food samples. Specifically, the government is excluding any solutions involving cell-cultured, lab-grown meat, or insect proteins, focusing instead on technologies between TRL 4 and 6. This is a Sources Sought Announcement for market research purposes and not a formal solicitation or a promise of future funding. Interested parties must submit a BAA preproposal by November 23, 2026, including a technical approach, past performance, and a rough order of magnitude cost estimate. Submissions must be sent via email to the designated points of contact and include the offeror's business size, NAICS code, and CAGE code to verify their Massachusetts location.
W6QK Acc-Apg Natick

POSTED

2 days ago

DEADLINE

in about 1 month
View Details
NAICS: 541714
New
SBIR / STTR
USDA SBIR/STTR Topic 8.2 — Plant Production and Protection - Biology
Solicitation # USDA-NIFA-TOPIC-8.2
The USDA National Institute of Food and Agriculture is soliciting proposals under Topic 8.2 for Plant Production and Protection - Biology. This initiative focuses on advancing crop production and protection through the development of innovative plant breeding methods, diagnostic technologies for diseases, and the creation of new food and non-food crop plants. Research efforts are directed toward improving plant characteristics to mitigate biotic and abiotic stresses, developing new genotypes for commercial applications, and creating tools to support the health of natural and domesticated pollinators. This opportunity is a total small business set-aside under the SBIR/STTR mandate, restricting eligibility to companies with fewer than 500 employees. Managed by the United States Department of Agriculture, the program is led by Dr. Christopher Philips. Interested parties can find further details and application guidelines through the NIFA website.
National Institute of Food and Agriculture

POSTED

3 days ago

DEADLINE

N/A
View Details
NAICS: 541714
New
Federal
Artificial Blood and Medical Consumable InnovationThe Artificial Blood and Medical Consumable Innovation subcontract supports the Defense Advanced Research Projects Agency within the Department of Defense. The scope of work involves providing innovative medical consumables and conducting biochemical research specifically focused on the development of artificial blood for prime contractors on DARPA Biological Technologies Office projects. The contractor is responsible for engineering scalable manufacturing processes for these consumables using sterile manufacturing facilities and bio-reactors. Key deliverables include the production of artificial blood prototypes and the implementation of scalable medical consumable solutions. This effort falls under NAICS code 541714, with a response deadline set for November 15, 2026.
Defense Advanced Research Projects Agcy

POSTED

5 days ago

DEADLINE

in 25 days
View Details
NAICS: 541714
New
Federal
Pre-Award Synopsis Texas Shield
Solicitation # DARPA-SN-27-07
The Defense Advanced Research Projects Agency (DARPA), through its Biological Technologies Office (BTO), intends to enter into an agreement with The University of Texas System consortium of universities for the Texas Shield Program. This integrated research initiative, identified by solicitation number DARPA-SN-27-07 and NAICS code 541714, focuses on developing autonomous and semi-autonomous medical technologies and scalable solutions for critical medical consumables. The primary goal is to support lifesaving medical care in contested, austere, and resource-limited environments. Key technical areas of focus include autonomous medical and robotic surgical systems, casualty evacuation, artificial-blood and supply innovation, AI-enabled clinical decision support, and mass-casualty science and simulation. This notice is a pre-award synopsis and is not a request for proposals or a competitive solicitation. Interested entities are invited to submit information by November 15, 2026, to TexasShieldxBTO@darpa.mil detailing their technical expertise, integrated research infrastructure, clinical-validation capabilities, and multi-institutional coordination capacity. Additionally, respondents must describe their consortium organizational structure, commercialization capabilities, facility clearance levels, and their ability to handle Controlled Unclassified Information. The government will not reimburse any costs associated with the preparation or submission of information in response to this notice.
Defense Advanced Research Projects Agcy

POSTED

5 days ago

DEADLINE

in 25 days
View Details
NAICS: 541714
New
Federal
Q--AMPLICON SEQUENCING SERVICES
Solicitation # 140G0226Q0047
Solicitation 140G0226Q0047 is a firm-fixed-price request for a Blanket Purchase Agreement (BPA) to provide next generation amplicon sequencing services for the USGS Upper Midwest Water Science Center’s Michigan Bacteriological Research Laboratory. The scope of work includes providing all equipment, labor, travel, and materials necessary to support research on bacterial pathogens, harmful algal blooms, microbial ecology, antibiotic resistance, and microbial source tracking. Key technical requirements include the use of Illumina MiSeq or AVITI sequencing technologies and the potential for library preparation for 16S V4 amplicon sequencing. The BPA has a total not-to-exceed value of 250,000 dollars with an estimated period of performance from September 17, 2026, to September 16, 2031. The award process prioritizes non-priced factors significantly over cost, focusing on the offeror's qualifications and technical performance. Evaluation criteria include a detailed listing of on-site equipment and calibration dates, personnel experience, internal quality assurance procedures, and a technical narrative not exceeding two pages. Performance will be executed in Lansing, Michigan, with delivery terms set as FOB Destination. Administrative requirements include electronic invoicing via the Internet Payment Platform and compliance with various federal regulations, including the Buy American Act and specific security prohibitions regarding telecommunications equipment. Proposals must be submitted to the USGS OAG Denver Acquisition Branch by September 11, 2026.
Ofc Of Acquisition Grants-Denver

POSTED

5 days ago

DEADLINE

in 2 days
View Details

More opportunities from Department Of Health And Human Services → Barda - Aspr / Daappo / Barda Dcma

Same awarding agency

NAICS: 541512
New
Federal
PHI Cybersecurity ImplementationThe PHI Cybersecurity Implementation subcontract, issued by the Department of Health and Human Services under BARDA, focuses on establishing robust cybersecurity frameworks to protect sensitive patient health information for medical device projects. The scope of work includes the deployment of secure cloud infrastructure, encryption protocols, and secure data transmission systems to ensure safe medical device connectivity. The selected provider will deliver a comprehensive secure data management system and a final cybersecurity certification. Strict adherence to regulatory and technical standards is required, specifically HIPAA compliance, NIST SP 800-53, and HITRUST standards. This opportunity falls under NAICS code 541512 and is based in Washington. Interested parties must submit their responses by November 18, 2026.
Computer Systems Design Services

POSTED

1 day ago

DEADLINE

in 28 days
View Details
NAICS: 493110
New
Federal
Medical Device Logistics and Surge DistributionThis subcontract for Medical Device Logistics and Surge Distribution supports prime contractors on BARDA medical device projects under the Department of Health and Human Services. The scope of work involves comprehensive warehousing, inventory management, and the rapid distribution of medical devices to hospitals and emergency departments. A critical component of the contract is the management of surge capacity for mass casualty events, utilizing climate-controlled facilities and medical-grade logistics software to ensure efficient delivery to designated care settings. To ensure safety and regulatory adherence, the provider must maintain strict compliance with Good Distribution Practice and HIPAA standards. The project is categorized under NAICS code 493110 and is centered in Washington. Interested parties should note the response deadline of November 18, 2026.
General Warehousing and Storage

POSTED

1 day ago

DEADLINE

in 28 days
View Details
NAICS: 325211
New
Federal
Medical-Grade Raw Material SupplyThis subcontract, titled Medical-Grade Raw Material Supply, involves the sourcing, quality testing, and delivery of essential raw materials used in the production of trauma and fracture-management devices. Supporting prime contractors on BARDA medical device projects under the Department of Health and Human Services, the scope of work focuses on providing medical-grade titanium, stainless steel, and specialized polymers. To ensure safety and efficacy, the contractor must provide full material certifications and maintain strict compliance with medical grade purity standards. The project is associated with NAICS code 325211 and is designated for performance in Washington, with a response deadline set for November 18, 2026.
Plastics Material and Resin Manufacturing

POSTED

1 day ago

DEADLINE

in 28 days
View Details
NAICS: 334510
New
Federal
Specialized Medical Component FabricationThis subcontract for Specialized Medical Component Fabrication involves the production of precision components for medical devices focused on trauma care and fracture stabilization. Working under prime contractors for BARDA projects within the Department of Health and Human Services, the selected provider will utilize precision CNC machining and molding to fabricate hardware from biocompatible polymers and medical-grade alloys. The contract requires strict adherence to FDA regulatory compliance and ISO 13485 certification to ensure the quality of the finished medical device components. Performance will take place in Washington, with a response deadline set for November 18, 2026.
Electromedical and Electrotherapeutic Apparatus Manufacturing

POSTED

1 day ago

DEADLINE

in 28 days
View Details
NAICS: 334510
New
Federal
Automated Ultrasound-Based, Super Intelligence (SI)-Enabled Fracture Detection
Solicitation # BARDA-FY27-10192026
The Center for Biomedical Advanced Research and Development Authority (BARDA) has issued Sources Sought Notice BARDA-FY27-10192026 to identify innovative medical countermeasure technologies for the rapid triage of musculoskeletal injuries, such as fractures and soft tissue injuries of extremities. This request for information is intended for planning and market research purposes to assess commercially available or nearing-commercial technologies that utilize Super Intelligence (SI) and machine learning for automated ultrasound-based fracture detection. The goal is to find standalone, point-of-care devices that can operate in emergency departments, urgent care centers, and austere field settings without relying on traditional imaging infrastructure like X-ray or CT scans. The desired technology must feature automated volumetric capture, 3D-rotatable modeling, and SI-enabled image processing that outperforms human imaging experts and has undergone FDA 510k clearance processes. BARDA is interested in ruggedized, portable units with sufficient battery life for disaster response, interoperability with electronic health record systems, and minimal training requirements for non-specialist operators. Potential acquisition strategies being explored include direct purchases, leases, or vendor-managed inventory arrangements. Interested small businesses and other than small business concerns under NAICS code 334510 must submit their capabilities statements by 1:00 p.m. Eastern Time on November 18, 2026. Submissions must include separate Technical and Business Representation sections, each limited to 10 pages in 12-point Times New Roman font, and be emailed to Justin Moore and Richard Hall. Responses should detail the company's manufacturing capabilities within the United States, regulatory maturity, supply chain resilience, and cybersecurity standards for handling sensitive patient health information.
Electromedical and Electrotherapeutic Apparatus Manufacturing

POSTED

1 day ago

DEADLINE

in 28 days
View Details
NAICS: 541714
Federal
Request for Proposals (RFP) - BARDA Vaccine Medical Countermeasures for Pandemic Influenza Preparedness & Response
Solicitation # 75A50126R00001_RFP_NPIVS_27
The Biomedical Advanced Research and Development Authority (BARDA) is soliciting proposals for the Vaccine Medical Countermeasures for Pandemic Influenza Preparedness and Response Program. The primary objective is to maintain a permanent readiness posture and commercially sustainable warm-base production capacity for the rapid manufacture of vaccines, antigens, and adjuvants during public health emergencies. Selected contractors will be responsible for producing countermeasures against influenza and other viruses with pandemic potential, generating necessary analytical, nonclinical, clinical, and chemistry, manufacturing, and controls data for FDA submission, and preparing candidate vaccine viruses. To be eligible, offerors must demonstrate successful experience in influenza vaccine manufacturing, evidenced by holding a U.S. influenza vaccine license or having submitted a Biologics License Application to the FDA. The contract is structured as an IDIQ with a five-year base period and a five-year option, totaling a potential 120-month ordering period. Award decisions will be based on the Highest Technically Rated Offerors with a Fair and Reasonable Price methodology, with a critical requirement for offerors to achieve a High Confidence rating in capabilities. Key deliverables include the submission of comprehensive manufacturing and supply chain continuity plans, surge readiness assessments, and strict adherence to CGMP guidelines and ASPR security requirements. Performance is monitored through a BARDA dose tracker, and final acceptance is contingent upon the submission of final reports and verified temperature control documentation during delivery. Invoicing is conducted quarterly via the Department of Treasury Invoice Processing Platform.
Research and Development in Biotechnology (except Nanobiotechnology)

POSTED

about 1 month ago

DEADLINE

in about 1 month
View Details
NAICS: 325412
Federal
Vaccine Lot Production (Research, Investigational, and Commercial)This subcontract involves the production of influenza vaccine antigens and vaccines across research, investigational, and commercial bulk scales to support prime contractors on BARDA pandemic preparedness projects. The work is performed within cGMP compliant facilities to ensure all investigational and commercial lots meet strict regulatory alignment and quality standards. Managed by the Department of Health and Human Services under the Barda agency, the contract focuses on delivering bulk vaccine lots across three distinct production scales. The opportunity is categorized under NAICS code 325412, with a response deadline set for October 30, 2026, and performance based in Washington.
Pharmaceutical Preparation Manufacturing

POSTED

2 months ago

DEADLINE

in 9 days
View Details
NAICS: 325412
Federal
cGMP Vaccine Seed Lot ManufacturingThis subcontract for cGMP Vaccine Seed Lot Manufacturing involves the production of yield-optimized Master Virus Seed, Working Virus Seed lots, or bacterial cell banks to support BARDA pandemic preparedness projects. The work is performed for prime contractors using qualified CVV reference strains within cGMP certified facilities that align with FDA-licensed vaccines or submitted BLAs. All seeds are characterized according to qualified internal standard operating procedures to ensure the delivery of certified lots. Managed by the Department of Health and Human Services under Barda, the contract falls under NAICS code 325412. The performance location is based in Washington, DC, with a response deadline of October 30, 2026.
Pharmaceutical Preparation Manufacturing

POSTED

2 months ago

DEADLINE

in 9 days
View Details
NAICS: 541714
Federal
Candidate Vaccine Virus (CVV) Development & CharacterizationThis subcontract, titled Candidate Vaccine Virus Development and Characterization, supports BARDA pandemic preparedness projects by preparing and characterizing both non-GLP and GLP influenza Candidate Vaccine Viruses. The scope of work includes performing HA/NA sequencing, genetic stability testing, ferret pathogenicity, two-way antigenicity, HA titer, sterility, and exclusivity. Additionally, the contractor is responsible for conducting plaque assays and chicken embryo lethality for HPAI strains within a BSL-2 environment, culminating in the delivery of final reports and Certificates of Analysis or Compliance. Managed by the Department of Health and Human Services under the Barda - Aspr agency, the project is categorized under NAICS code 541714. The performance location is based in Washington, DC. The solicitation was posted on August 17, 2026, with a response deadline set for October 30, 2026.
Research and Development in Biotechnology (except Nanobiotechnology)

POSTED

2 months ago

DEADLINE

in 9 days
View Details
NAICS: 326199
Federal
Specialized Material Supply (Vials, Stoppers, Seals)This subcontract for Specialized Material Supply focuses on providing critical medical-grade components, including vials, stoppers, seals, and crimps, to support prime contractors on BARDA pandemic preparedness projects. The scope of work requires the delivery of physical inventory and the provision of comprehensive supply chain narratives that detail the country of origin and tariff exposure for all containment and closure materials. Managed by the Department of Health and Human Services under the agency Barda - Aspr / Daappo / Barda Dcma, the contract is categorized under NAICS code 326199. The place of performance is located in Washington, DC, with a response deadline set for October 30, 2026.
All Other Plastics Product Manufacturing

POSTED

2 months ago

DEADLINE

in 9 days
View Details
NAICS: 493110
Federal
Labeling, Packaging, and Cold Chain StorageThis subcontract, managed by the Department of Health and Human Services under BARDA, focuses on providing essential labeling, packaging, and specialized stability storage for bulk and final vaccine products. The scope of work involves supporting prime contractors on pandemic preparedness projects by managing cold chain logistics and stability monitoring for commercial scale bulk antigens, final containers, and bulk adjuvants. The contractor is responsible for the delivery of packaged products and the provision of detailed stability reports. This opportunity is categorized under NAICS code 493110 and is based in Washington, DC. The response deadline for this requirement is October 30, 2026.
General Warehousing and Storage

POSTED

2 months ago

DEADLINE

in 9 days
View Details
NAICS: 325412
Federal
Formulation, Filling, and Finishing ServicesThis subcontract for Formulation, Filling, and Finishing Services supports BARDA pandemic preparedness projects by providing final formulation and filling of antigens, adjuvants, or co-formulated products into final containers. The work is performed under cGMP compliant processes within sterile filling environments to ensure the delivery of high-quality filled vials and containers for prime contractors. The opportunity is managed by the Department of Health and Human Services under the Barda - Aspr / Daappo / Barda Dcma agency and is categorized under NAICS code 325412. The project is based in Washington, DC, with a response deadline of October 30, 2026.
Pharmaceutical Preparation Manufacturing

POSTED

2 months ago

DEADLINE

in 9 days
View Details

Ready to Pursue This Opportunity?

Get AI-powered intelligence on this solicitation and the ones like it

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS